Carissimi Francesca, Barbaglia Matteo Nazzareno, Salmi Livia, Ciulli Cristina, Roccamatisi Linda, Cordaro Giuseppe, Mallela Venkata Ramana, Minisini Rosalba, Leone Biagio Eugenio, Donadon Matteo, Torzilli Guido, Pirisi Mario, Romano Fabrizio, Famularo Simone
School of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy.
Department of Translational Medicine, Università del Piemonte Orientale, Novara 28100, Italy.
World J Gastrointest Surg. 2021 Sep 27;13(9):967-978. doi: 10.4240/wjgs.v13.i9.967.
The treatment for hepatocellular carcinoma (HCC) relies on liver resection, which is, however, burdened by a high rate of recurrence after surgery, up to 60% at 5 years. No pre-operative tools are currently available to assess the recurrence risk tailored to every single patient. Recently liquid biopsy has shown interesting results in diagnosis, prognosis and treatment allocation strategies in other types of cancers, since its ability to identify circulating tumor cells (CTCs) derived from the primary tumor. Those cells were advocated to be responsible for the majority of cases of recurrence and cancer-related deaths for HCC. In fact, after being modified by the epithelial-mesenchymal transition, CTCs circulate as "seeds" in peripheral blood, then reach the target organ as dormant cells which could be subsequently "awakened" and activated, and then initiate metastasis. Their presence may justify the disagreement registered in terms of efficacy of anatomic non-anatomic resections, particularly in the case of microvascular invasion, which has been recently pointed as a histological sign of the spread of those cells. Thus, their presence, also in the early stages, may justify the recurrence event also in the contest of liver transplant. Understanding the mechanism behind the tumor progression may allow improving the treatment selection according to the biological patient-based characteristics. Moreover, it may drive the development of novel biological tailored tests which could address a specific patient to neoadjuvant or adjuvant strategies, and in perspective, it could also become a new method to allocate organs for transplantation, according to the risk of relapse after liver transplant. The present paper will describe the most recent evidence on the role of CTCs in determining the relapse of HCC, highlighting their potential clinical implication as novel tumor behavior biomarkers able to influence the surgical choice.
肝细胞癌(HCC)的治疗依赖于肝切除术,然而,该手术存在术后高复发率的问题,5年复发率高达60%。目前尚无术前工具可用于评估针对每一位患者的复发风险。最近,液体活检在其他类型癌症的诊断、预后和治疗分配策略方面显示出了有趣的结果,因为它能够识别源自原发性肿瘤的循环肿瘤细胞(CTC)。这些细胞被认为是导致HCC大多数复发病例和癌症相关死亡的原因。事实上,经上皮-间质转化修饰后,CTC作为“种子”在外周血中循环,然后以休眠细胞的形式到达靶器官,随后可能被“唤醒”并激活,进而引发转移。它们的存在可能解释了在解剖性与非解剖性切除疗效方面存在的分歧,特别是在微血管侵犯的情况下,微血管侵犯最近被指出是这些细胞扩散的组织学标志。因此,即使在早期阶段它们的存在也可能解释肝移植情况下的复发事件。了解肿瘤进展背后的机制可能有助于根据患者的生物学特征改进治疗选择。此外,这可能推动新型生物定制检测的发展,这些检测可以针对特定患者采用新辅助或辅助策略,从长远来看,根据肝移植后的复发风险,它还可能成为一种新的器官分配方法。本文将描述关于CTC在决定HCC复发中作用的最新证据,强调它们作为能够影响手术选择的新型肿瘤行为生物标志物的潜在临床意义。